Secondary prevention of cardiovascular disease in high-risk patients diagnosed with cardiovascular disease (status post myocardial infarction or stroke, peripheral arterial disease), type 2 diabetes, or moderate to severe chronic kidney disease (CKD 4-5): in patients who cannot be diagnosed with FH according to Dutch criteria, although they have lipid disorders and do not achieve their LDL-C targets, according to the adopted guidelines (), and in whom all other standard therapies have failed (for at least 3 months) or are poorly tolerated, and/or there are contraindications to pharmacological treatment (adverse effects, complications, e.g
This narrative approach allowed for comprehensive synthesis of current evidence while maintaining the flexibility to include diverse study designs and clinical perspectives relevant to understanding all aspects of DPN
Plus, it's incredibly effective
Its important for patients to follow the dosage and schedule provided, and not to stop a medication early or take more than recommended without consulting the prescriber
Data Availability Statement All the data and materials are included in the article.
Enhanced Fibroblast Activation : RLT energizes fibroblasts, while GHK-Cu directs their activity toward ECM rebuilding
